Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
CSTL
CSTL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
CSTL News
AIGH Capital Fully Exits Lumen Technologies Stake
Feb 03 2026
Fool
Castle Biosciences Expects 2025 Revenue to Exceed $340 Million
Jan 11 2026
Globenewswire
AstraZeneca Secures FDA Approval for Enhertu in First-Line Breast Cancer, Triggers $150M Milestone Payment
Dec 23 2025
NASDAQ.COM
Novo Nordisk Submits NDA for Advanced Obesity Treatment CagriSema
Dec 19 2025
NASDAQ.COM
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
Dec 19 2025
Globenewswire
Castle Biosciences Grants 139,494 RSUs to 83 Employees as Inducement
Dec 19 2025
Newsfilter
Castle Biosciences Releases New Data Enhancing Prognostic Accuracy for Uveal Melanoma
Dec 17 2025
Globenewswire
Castle Biosciences Releases New Data Enhancing Prognostic Accuracy for Uveal Melanoma
Dec 17 2025
Newsfilter
FDA Approves Fast Track Status for ADAG's Colorectal Cancer Treatment
Dec 17 2025
NASDAQ.COM
Castle Biosciences (CSTL): Assessment of Valuation Following Expert Panel Approval of DecisionDx-Melanoma Test
Dec 13 2025
Yahoo Finance
Castle Biosciences Publishes Study Validating TissueCypher Test for Barrett's Esophagus Risk Stratification
Dec 12 2025
Globenewswire
Castle Biosciences Publishes Study Validating TissueCypher Test's Risk Stratification Capabilities
Dec 12 2025
Newsfilter
Castle Biosciences Publishes Expert Consensus on 31-Gene Test for Melanoma
Dec 09 2025
Newsfilter
FDA Greenlights MRK's Keytruda and Keytruda SC Combination for Bladder Cancer Treatment
Nov 24 2025
NASDAQ.COM
Insmed Shares Climb Following EU Approval of Lung Disease Treatment, Brinsupri
Nov 19 2025
NASDAQ.COM
Zacks.com Spotlights Perimeter Solutions, Interface, Castle Biosciences, and Great Lakes Dredge & Dock
Nov 17 2025
NASDAQ.COM
Show More News
